Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Haemonetics Corp (NYSE: HAE) closed at $54.54 up 0.37% from its previous closing price of $54.34. In other words, the price has increased by $0.37 from its previous closing price. On the day, 0.77 million shares were traded. HAE stock price reached its highest trading level at $55.1202 during the session, while it also had its lowest trading level at $54.02.
Ratios:
For a deeper understanding of Haemonetics Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.89. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.72. In the meantime, Its Debt-to-Equity ratio is 1.39 whereas as Long-Term Debt/Eq ratio is at 1.04.
On August 08, 2025, Barrington Research reiterated its Outperform rating and also upped its target price recommendation from $95 to $86. JP Morgan Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $62.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 26 ’25 when Llorens Josep bought 18,630 shares for $74.94 per share.
Strong Stewart W bought 708 shares of HAE for $50,593 on Jun 12 ’25. On Jun 04 ’25, another insider, Strong Stewart W, who serves as the Officer of the company, bought 7,705 shares for $69.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 2627589888 and an Enterprise Value of 3558943488. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.65, and their Forward P/E ratio for the next fiscal year is 9.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95 while its Price-to-Book (P/B) ratio in mrq is 2.98. Its current Enterprise Value per Revenue stands at 2.644 whereas that against EBITDA is 9.63.
Stock Price History:
The Beta on a monthly basis for HAE is 0.37, which has changed by -0.2734781 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $94.99, while it has fallen to a 52-week low of $50.68. The 50-Day Moving Average of the stock is -19.61%, while the 200-Day Moving Average is calculated to be -22.06%.
Shares Statistics:
For the past three months, HAE has traded an average of 797.47K shares per day and 961710 over the past ten days. A total of 48.16M shares are outstanding, with a floating share count of 47.51M. Insiders hold about 1.39% of the company’s shares, while institutions hold 113.31% stake in the company. Shares short for HAE as of 1755216000 were 4370093 with a Short Ratio of 5.48, compared to 1752537600 on 3500606. Therefore, it implies a Short% of Shares Outstanding of 4370093 and a Short% of Float of 12.049999999999999.
Earnings Estimates
The market rating for Haemonetics Corp (HAE) is a result of the insights provided by 11.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $1.27, with high estimates of $1.35 and low estimates of $1.2.
Analysts are recommending an EPS of between $4.9 and $4.73 for the fiscal current year, implying an average EPS of $4.83. EPS for the following year is $5.49, with 10.0 analysts recommending between $5.81 and $5.19.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $312.14M this quarter.It ranges from a high estimate of $319.29M to a low estimate of $301.7M. As of the current estimate, Haemonetics Corp’s year-ago sales were $345.51MFor the next quarter, 11 analysts are estimating revenue of $328.66M. There is a high estimate of $335.59M for the next quarter, whereas the lowest estimate is $316.84M.
A total of 11 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.31B, while the lowest revenue estimate was $1.27B, resulting in an average revenue estimate of $1.3B. In the same quarter a year ago, actual revenue was $1.36BBased on 10 analysts’ estimates, the company’s revenue will be $1.38B in the next fiscal year. The high estimate is $1.42B and the low estimate is $1.34B.
